The Collaborative Trajectory Analysis Project (cTAP)
We are enabling leading clinical experts to solve critical problems in Duchenne drug development, now
Reap the benefits of collaboration, without the downsides
Unleash the power of patient data equitably, retain full control over the use of your data, align your funds with your priorities, simplify the ‘how’.
The right team, the best analytic solutions, today
Unrivaled academic access to skilled professionals, experienced in assembling the right teams connecting data and analytics, at scale, to solve practical challenges in rare disease drug development.
Empowered Drug Development
Conduct the right trial, the first time
Accelerate learning from natural history, explain phenotypic heterogeneity, access prognostic models and analytic tools to test trial designs iteratively and in real time.
Why We’re Here
Most pivotal trials in Duchenne have failed.
Have drug effects been hidden by unexpectedly high variability in patient outcomes? Or do the drugs not work?
In hindsight, trials have been clouded by high variability in rates of disease progression among patients.
Entered Clinical Trials
Shared Vision: Not bigger trials, smarter trials.
Clinical trials offer hope for Duchenne patients and families. Yet, clinical trials are taxing. All demand a major commitment of time and effort.
Almost 500 of the 1200+ patients enrolled in recent trials were assigned to placebo treatment.
Patients deserve clinical trials that reliably test the efficacy of a drug- not how well (or poorly) natural history is understood.
The cTAP team is an unprecedented coalition of leaders bound together by common purpose and mutual respect, creativity in overcoming traditional barriers, and an unrelenting sense of urgency.
Clinical Experts in Duchenne
Catholic University, Rome
University College London
Cincinnati Children's Hospital
University of California, Davis
Children’s Hospital of Philadelphia
Wave Life Sciences
Parent Project Muscular Dystrophy
Analytic and Collaboration Leaders
Analysis Group Inc.
Susan J. Ward
The TAP Collaboration
Eli Lilly and Company joins cTAP, helping to accelerate enriched clinical trial design for the provision of new treatments for Duchenne Muscular Dystrophy patients
Marathon Pharmaceuticals and Italfarmaco Join cTAP:Learning from Patient Data to Enhance Clinical Trial Design for Duchenne Muscular Dystrophy
Summit joins cTAP In Collaborative Effort To Enhance The Development Of Uthrophin Modulators And Other Treatments For Duchenne Muscular Dystrophy
cTAP Announces Two Research Publications Categorizing and Predicting Disease Progression in Duchenne Muscular Dystrophy
Nonprofits, Pharmaceutical Companies and Noted Clinicians Join to Launch the Collaborative Trajectory Analysis Project (cTAP), Advancing Clinical Trial Design for Duchenne Muscular Dystrophy
Consortium Working Together to Bring Quality of Life Treatments to the Duchenne Community
Prognostic model for 1 year change in 6MWD
Individualized prediction of changes in 6- minute walk distance for patients with Duchenne muscular dystrophy.
Nathalie Goemans, Marleen vanden Hauwe, James Signorovitch, Elyse Swallow, Jinlin Song, for the Collaborative Trajectory Analysis Project (cTAP). PLoS One, 2016, 0164684
Clusters of patients with differing longitudinal trajectories
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.
Eugenio Mercuri, James Edward Signorovitch, Elyse Swallow, Jinlin Song, and Susan J. Ward for the Trajectory Analysis Project Collaboration (cTAP) and the DMD Italian group. Neuromuscular Disorders 26 (2016) 576–583